ArticleJournal of family medicine and primary care2026
Triglyceride Glucose Index as a screening tool for subclinical heart failure with preserved ejection fraction in type 2 diabetes mellitus in resource-limited settings.
Article in Journal of family medicine and primary care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Context: Diabetic cardiomyopathy is an entity with a multifactorial pathophysiology, in which insulin resistance plays a key role. It increases the risk of heart failure with preserved ejection fraction (HFpEF) in type 2 diabetes mellitus (T2DM). The Triglyceride-Glucose Index (TGI) is a novel measure of insulin resistance which is simple to use and may serve as an accessible marker for subclinical HFpEF. Aims: To evaluate the association between TGI and subclinical HFpEF in asymptomatic patients with T2DM and assess its diagnostic performance. Methods: This was a cross-sectional observational analytic study in which 274 asymptomatic T2DM patients aged 18-60 years were enrolled. Patients with known cardiovascular disease, hypertension, macro- and microvascular complications, and other major comorbidities were excluded. TGI was calculated, and all participants underwent 2D echocardiography to assess left ventricular diastolic function. Results: LV diastolic dysfunction (LVDD) was detected in 62.4% of participants. TGI was significantly higher in patients with LVDD (mean 9.69 ± 0.49) versus those without (mean 9.23 ± 0.63), Conclusions: TGI demonstrates fair diagnostic accuracy for identifying subclinical HFpEF in T2DM. Given its simplicity and cost-effectiveness, it may be considered a valuable screening tool in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.